In contrast, MMI is not associated with severe liver failure in children  or with high prevalence of MPO-ANCA 
In contrast, MMI is not associated with severe liver failure in children  or with high prevalence of MPO-ANCA . of the autoimmune process involving all thyroid antigens; therefore, the term autoimmune hyperthyroidism seems to be more appropriate than classical GD in this group of patients. The first-choice treatment with methimazole rarely causes adverse events during the therapy, and they have benign character. = 59) were treated with ALW-II-41-27 methimazole (MMI), only one patient received propylthiouracil (PTU) as initial therapy. Adverse drug reactions occurred in 13 patients (21.67%): hive (= 3), pruritus (= 1), leucopaenia (= 4), elevated liver enzymes (= 4), and purpuric skin lesions (= 1). Thirty-two children (53%) developed hypothyroidism during the first course of ATD treatment and simultaneously received supplementation with L-thyroxin. Remission ALW-II-41-27 was defined as being euthyroid for one year after cessation of therapy . Relapse was defined as recurrence of hyperthyroidism at any time during the treatment or after withdrawal of thyrostatics. In 56 children under observation longer than three months after starting ATD treatment, prolonged TSH suppression ( 3 months) was found in 18 (32%) patients. In 31 children observed 24 months, relapses after first-line treatment occurred in 10 patients (32%), and relapses after completion of antithyroid drug therapy occurred in six patients (19%). In children observed 24 months (= 29) relapses after first-line treatment were found in 14 patients (48%). Ten patients were referred for radioiodine therapy, and one patient was qualified for strumectomy. Comparison of medical data of patients diagnosed with Graves disease in two decades following implementation of iodine prophylaxis programme In our centre there were 34 newly diagnosed patients in FDG and 60 patients in SDG. No statistically significant difference in the mean age and sex contribution at diagnosis between groups was found. Familial prevalence of GD was significantly more frequent in FDG than in SDG (29% vs. 7%; = 0.004). The mean value of TRAb was higher in SDG, but no statistical significance was found ( 0.05). Occurrence of thyroid autoimmune ophthalmopathy (TAO) in the second decade decreased (44% vs. 28.3%); however, the difference was not statistically significant ( 0.05). Severe side effects of ATDs were observed significantly more often in Rabbit Polyclonal to MCL1 FDG than in SDG ( 0.05). All other clinical features of GD between FDG and SDG did not differ significantly (Table 3). Table 3 Clinical characteristics of children with Graves disease ALW-II-41-27 C two decades after mandatory salt iodination (%)34 (100)60 (100)C?Girls28 (82.4)52 (86.67)NS?Boys6 (17.7)8 (13.33)CMean age11.7 ye (6.4-16.4)13.7 ye (3.3-17.5)NSPositive family history of thyroid disease13 (38)18 (30)NSPositive family history of Graves disease10 (29)4 (7)0.004*Other autoimmune disease4 (11.7)5 (8.3)NSDisorders with predisposition to autoimmune diseaseDown syndrome: 3 (9)Down syndrome: 1 (1.7)Allergic disease8 (23.5)12 (20)NSMean TRAb value8.87 IU/l (3.6-19 IU/l)12.23 IU/l (2.46-40 IU/l)NSPresence of TAO15 (44)17 (28.3)NS, 0.11Side effects of ATDs6 (17)13 (21.67)NSSevere side effects of ATDs3 (8.5)00.02* Open in a separate window n C number of patients, FDG C first decade group, SDG C second decade group, TRAb C TSH receptor antibodies, NS C no statistical significance *statistically significant value, TAO C thyroid autoimmune ophthalmopathy, ATDs C anti-thyroid drugs Discussion In our study, the two-fold higher number of patients in SDG suggests increasing incidence of GD in children in the last 10 years. However, the study was a single-centre observation, hence it does not have epidemiological value. The next.